, Tracking Stock Market Picks
Enter Symbol:
Biogen Idec Inc (BIIB) [hlAlert]

down 4.33 %

Biogen Idec Inc (BIIB) rated Buy with price target $377 by Brean Capital

Posted on: Thursday,  Jan 30, 2014  8:25 AM ET by Brean Capital

Brean Capital rated Buy Biogen Idec Inc (NASDAQ: BIIB) on 01/30/2014, when the stock price was $318.28. Since
then, Biogen Idec Inc has lost 4.33% as of 01/07/2016's recent price of $304.49.
If you would have followed this Brean Capital's recommendation on BIIB, you would have lost 4.33% of your investment in 707 days.

Biogen Idec Inc. is engaged in the development, manufacturing, and commercialization of therapies. The Company?s products address diseases such as multiple sclerosis, non-Hodgkin?s lymphoma (NHL), rheumatoid arthritis (RA), crohn?s disease (CD) and psoriasis. The Company has four products: AVONEX (interferon beta-1a), RITUXAN (rituximab), TYSABRI (natalizumab) and FUMADERM (dimethylfumarate and monoethylfumarate salts). AVONEX is used in the treatment of relapsing forms of multiple sclerosis (MS). RITUXAN is one of the selling oncology therapeutics. In the United States, RITUXAN is approved for NHL. TYSABRI is approved for the treatment of relapsing forms of MS. FUMADERM acts as an immunomudulator. The Company also has product candidates, such as BG-12, which is a oral fumarate; ANTI-CD80 monoclonal antibody (MAb)(galiximab); ANTI-CD23 MAb (lumiliximab); Humanized Anti-CD20 MAb (ocrelizumab), Lixivaptan, an oral compound for the potential treatment of hyponatremia, and ADENTRI.

Brean Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/30/2014 8:25 AM Buy
318.28 377.00
as of 10/17/2014
1 Week down  -2.67 %
1 Month down  -6.37 %
3 Months up  2.47 %
1 YTD down  -3.63 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy